Based on the synergistic antitumor activity profiles of combined APG and TRAIL treatments in vitro and in vivo and the absence of cytotoxicity in normal tissues, we believe that APG has strong therapeutic value for use in combination with TRAIL against lung cancer that warrants further investigation. The gene discussed is TNFSF10; the disease is lung cancer.